Literature DB >> 28742619

Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers.

Angeline L Wang1, Eric Weinlander, Brandon M Metcalf, Neal P Barney, David M Gamm, Sarah M Nehls, Michael C Struck.   

Abstract

PURPOSE: To report the clinical course of 6 patients with refractory neurotrophic corneal ulcers that were treated with topical insulin drops.
METHODS: Retrospective chart review of patients who had neurotrophic corneal ulcers or epithelial defects refractory to standard medical and surgical treatment. Insulin drops, prepared by mixing regular insulin in artificial tears with a polyethylene glycol and propylene glycol base at a concentration of 1 unit per milliliter, were prescribed 2 to 3 times daily.
RESULTS: Six patients, aged 2 to 73 years, developed neurotrophic corneal ulcers refractory to a range of medical and surgical treatments, including bandage contact lens, amniotic membrane grafting, and permanent tarsorrhaphy. Each patient was administered topical insulin drops with complete corneal reepithelialization within 7 to 25 days.
CONCLUSIONS: Topical insulin may be a simple and effective treatment for refractory neurotrophic corneal ulcers. Further study is required to determine the clinical efficacy and side effect profile of insulin drops.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28742619      PMCID: PMC5633504          DOI: 10.1097/ICO.0000000000001297

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  10 in total

1.  THE USE OF INSULIN IN THE TREATMENT OF CORNEAL ULCERS.

Authors:  T R Aynsley
Journal:  Br J Ophthalmol       Date:  1945-07       Impact factor: 4.638

2.  Topical insulin in wound healing: a randomised, double-blind, placebo-controlled trial.

Authors:  S E Greenway; L E Filler; F L Greenway
Journal:  J Wound Care       Date:  1999-11       Impact factor: 2.072

3.  Topical application of insulin in the treatment of decubitus ulcers: a pilot study.

Authors:  S R Van Ort; R M Gerber
Journal:  Nurs Res       Date:  1976 Jan-Feb       Impact factor: 2.381

Review 4.  Topical insulin for healing of diabetic epithelial defects?: A retrospective review of corneal debridement during vitreoretinal surgery in Malaysian patients.

Authors:  M L C Bastion; K P Ling
Journal:  Med J Malaysia       Date:  2013-06

5.  Persistent epithelial defects due to neurotrophic keratopathy treated with a substance p-derived peptide and insulin-like growth factor 1.

Authors:  Teruo Nishida; Tai-Ichiro Chikama; Naoyuki Morishige; Ryoji Yanai; Naoyuki Yamada; Jun Saito
Journal:  Jpn J Ophthalmol       Date:  2007-12-21       Impact factor: 2.447

Review 6.  Advances in treatment for neurotrophic keratopathy.

Authors:  Teruo Nishida; Ryoji Yanai
Journal:  Curr Opin Ophthalmol       Date:  2009-07       Impact factor: 3.761

7.  Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy.

Authors:  N Yamada; R Matsuda; N Morishige; R Yanai; T-i Chikama; T Nishida; T Ishimitsu; A Kamiya
Journal:  Br J Ophthalmol       Date:  2008-05-29       Impact factor: 4.638

8.  Repeated monitoring of corneal nerves by confocal microscopy as an index of peripheral neuropathy in type-1 diabetic rodents and the effects of topical insulin.

Authors:  Debbie K Chen; Katie E Frizzi; Lucie S Guernsey; Kelsey Ladt; Andrew P Mizisin; Nigel A Calcutt
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

9.  Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus.

Authors:  Ian S Zagon; Matthew S Klocek; Joseph W Sassani; Patricia J McLaughlin
Journal:  Arch Ophthalmol       Date:  2007-08

10.  Insulin, not leptin, promotes in vitro cell migration to heal monolayer wounds in human corneal epithelium.

Authors:  Lynne J Shanley; Colin D McCaig; John V Forrester; Min Zhao
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-04       Impact factor: 4.799

  10 in total
  7 in total

1.  Insulin facilitates corneal wound healing in the diabetic environment through the RTK-PI3K/Akt/mTOR axis in vitro.

Authors:  C Peterson; H L Chandler
Journal:  Mol Cell Endocrinol       Date:  2022-02-26       Impact factor: 4.369

2.  Efficacy of treatments for neurotrophic keratopathy: a systematic review and meta-analysis.

Authors:  Sébastien Roumeau; Frédéric Dutheil; Vincent Sapin; Julien S Baker; Stephanie L Watson; Bruno Pereira; Frédéric Chiambaretta; Valentin Navel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

Review 3.  Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets.

Authors:  Deanna H Dang; Kamran M Riaz; Dimitrios Karamichos
Journal:  Drugs       Date:  2022-01-13       Impact factor: 9.546

Review 4.  New Pharmacological Approaches for the Treatment of Neurotrophic Keratitis.

Authors:  Su Yin Koay; Daniel F P Larkin
Journal:  Front Pharmacol       Date:  2022-03-22       Impact factor: 5.810

Review 5.  Neurotization of the human cornea - A comprehensive review and an interim report.

Authors:  Anubha Rathi; Nandini Bothra; Smruti R Priyadarshini; Divya S R Achanta; Merle Fernandes; Somasheila I Murthy; Anasua G Kapoor; Tarjani V Dave; Suryasnata Rath; Rajesh Yellinedi; Rambabu Nuvvula; Gautam Dendukuri; Milind N Naik; Muralidhar Ramappa
Journal:  Indian J Ophthalmol       Date:  2022-06       Impact factor: 2.969

6.  Using Convolutional Neural Network as a Statistical Algorithm to Explore the Therapeutic Effect of Insulin Liposomes on Corneal Inflammation.

Authors:  Yukun Liao; Huiting Jiang; Yangrui Du; Xiaojing Xiong; Yu Zhang; Zhiyu Du
Journal:  Comput Intell Neurosci       Date:  2022-07-31

Review 7.  The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease.

Authors:  Whitney L Stuard; Rossella Titone; Danielle M Robertson
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-03       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.